Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer-5

<p><b>Copyright information:</b></p><p>Taken from "Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer"</p><p>BMC Biotechnology 2007;7():35-35.</p><p>Published online 26 Jun 2007</p><p>PMCID:PMC1913502.</p><p></p>oclonal anti-CAR antibody and an APAAP detection system

Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer-0

<p><b>Copyright information:</b></p><p>Taken from "Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer"</p><p>BMC Biotechnology 2007;7():35-35.</p><p>Published online 26 Jun 2007</p><p>PMCID:PMC1913502.</p><p></p>s. VP16: Herpes simplex virus transactivator gene, TetR: Tetracycline repressor gene, TKmin: Thymidine kinase minimal promoter, TetO7: Tetracycline operator (seven copies), CMVmin: Cytomegalovirus minimal promoter, hscIL-12: human single-chain IL-12 gene, Amp R: ampicillin resistance gene, ITR: inverted terminal repeat, pA: poly-A from the bovine growth hormone gene

Additional file 1: of Design and rationale of the ATHENA study – A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial

List of ethics committees. (PDF 184 kb

Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer-2

<p><b>Copyright information:</b></p><p>Taken from "Cloning and characterization of an adenoviral vector for highly efficient and doxycycline – suppressible expression of bioactive human single – chain interleukin 12 in colon cancer"</p><p>BMC Biotechnology 2007;7():35-35.</p><p>Published online 26 Jun 2007</p><p>PMCID:PMC1913502.</p><p></p

IKK1 aggravates ischemia-reperfusion kidney injury by promoting the differentiation of effector T cells

Ischemia-reperfusion injury (IRI) is one of the major causes of acute kidney injury (AKI), and experimental work has revealed detailed insight into the inflammatory response in the kidney. T cells and NFκB pathway play an important role in IRI. Therefore, we examined the regulatory role and mechanisms of IkappaB kinase 1 (IKK1) in CD4+T lymphocytes in an experimental model of IRI. IRI was induced in CD4cre and CD4IKK1Δ mice. Compared to control mice, conditional deficiency of IKK1 in CD4+T lymphocyte significantly decreased serum creatinine, blood urea nitrogen (BUN) level, and renal tubular injury score. Mechanistically, lack in IKK1 in CD4+T lymphocytes reduced the ability of CD4 lymphocytes to differentiate into Th1/Th17 cells. Similar to IKK1 gene ablation, pharmacological inhibition of IKK also protected mice from IRI. Together, lymphocyte IKK1 plays a pivotal role in IRI by promoting T cells differentiation into Th1/Th17 and targeting lymphocyte IKK1 may be a novel therapeutic strategy for IRI. </p